Baupost Group’s Atara Biotherapeutics ATRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-390,945
| Closed | -$14.5M | – | 25 |
|
|
2023
Q3 | $14.5M | Hold |
390,945
| – | – | 0.28% | 30 |
|
|
2023
Q2 | $15.7M | Buy |
390,945
+26,000
| +7% | +$1.47M | 0.28% | 25 |
|
|
2023
Q1 | $26.5M | Buy |
364,945
+40,000
| +12% | +$3.88M | 0.45% | 23 |
|
|
2022
Q4 | $26.6M | Hold |
324,945
| – | – | 0.43% | 25 |
|
|
2022
Q3 | $30.7M | Hold |
324,945
| – | – | 0.53% | 26 |
|
|
2022
Q2 | $63.3M | Hold |
324,945
| – | – | 0.94% | 23 |
|
|
2022
Q1 | $75.5M | Sell |
324,945
-14,155
| -4% | -$4.51M | 0.81% | 22 |
|
|
2021
Q4 | $134M | Hold |
339,100
| – | – | 1.32% | 23 |
|
|
2021
Q3 | $152M | Hold |
339,100
| – | – | 1.39% | 21 |
|
|
2021
Q2 | $132M | Hold |
339,100
| – | – | 1.07% | 24 |
|
|
2021
Q1 | $122M | Sell |
339,100
-25,260
| -7% | -$11.2M | 0.97% | 28 |
|
|
2020
Q4 | $179M | Sell |
364,360
-32,521
| -8% | -$15M | 1.65% | 17 |
|
|
2020
Q3 | $129M | Hold |
396,881
| – | – | 1.39% | 23 |
|
|
2020
Q2 | $145M | Buy |
396,881
+64,525
| +19% | +$16.3M | 1.8% | 18 |
|
|
2020
Q1 | $70.7M | Hold |
332,356
| – | – | 1.04% | 22 |
|
|
2019
Q4 | $137M | Hold |
332,356
| – | – | 1.51% | 20 |
|
|
2019
Q3 | $117M | Buy |
332,356
+52,356
| +19% | +$19.5M | 1.33% | 22 |
|
|
2019
Q2 | $141M | Buy |
280,000
+24,779
| +10% | +$17.5M | 1.27% | 23 |
|
|
2019
Q1 | $254M | Buy |
255,221
+5,036
| +2% | +$4.68M | 2.13% | 16 |
|
|
2018
Q4 | $217M | Hold |
250,185
| – | – | 1.89% | 16 |
|
|
2018
Q3 | $259M | Hold |
250,185
| – | – | 1.98% | 16 |
|
|
2018
Q2 | $230M | Hold |
250,185
| – | – | 2.01% | 14 |
|
|
2018
Q1 | $244M | Buy |
250,185
+35,800
| +17% | +$32.6M | 2.35% | 14 |
|
|
2017
Q4 | $97M | Hold |
214,385
| – | – | 0.96% | 20 |
|
|
2017
Q3 | $88.7M | Hold |
214,385
| – | – | 1.11% | 17 |
|
|
2017
Q2 | $75M | Hold |
214,385
| – | – | 0.86% | 20 |
|
|
2017
Q1 | $110M | Hold |
214,385
| – | – | 1.3% | 19 |
|
|
2016
Q4 | $76.1M | Hold |
214,385
| – | – | 0.99% | 19 |
|
|
2016
Q3 | $115M | Hold |
214,385
| – | – | 1.63% | 18 |
|
|
2016
Q2 | $121M | Hold |
214,385
| – | – | 1.64% | 16 |
|
|
2016
Q1 | $102M | Hold |
214,385
| – | – | 1.47% | 16 |
|
|
2015
Q4 | $142M | Hold |
214,385
| – | – | 2.57% | 9 |
|
|
2015
Q3 | $169M | Buy |
214,385
+22,000
| +11% | +$26.8M | 2.81% | 10 |
|
|
2015
Q2 | $254M | Buy |
192,385
+1,854
| +1% | +$2.13M | 4.23% | 10 |
|
|
2015
Q1 | $193M | Buy |
190,531
+90,694
| +91% | +$59.9M | 3.24% | 11 |
|
|
2014
Q4 | $59.1M | Buy |
+99,837
| New | +$61M | 1.16% | 20 |
|
Other funds holding ATRA
EC
RG
Baupost Group's ATRA Position: Q4 2023 in Review
Baupost Group sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 390,945 shares — an estimated $14.5M sold.
Baupost Group first reported a position in ATRA in Q4 2014 and held it in 36 quarters. The position peaked at $259M in Q3 2018. 89 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.
- Baupost Group reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
- Baupost Group sold 390,945 Atara Biotherapeutics shares in Q4 2023, an estimated $14.5M.
- Baupost Group first reported a position in Atara Biotherapeutics in Q4 2014 and held it in 36 quarters.
- Baupost Group's Atara Biotherapeutics position peaked at $259M in Q3 2018.
- 89 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.
Based on Baupost Group's 13F filing for Q4 2023, filed 13 Feb 2024.